CD8A and neoplasm: Antiangiogenesis agents, such as levantinib, axitinib, bevacizumab, and cabozantinib, have been reported to improve CD8+ T cell infiltration and activation via tumor vasculature normalization and suppression of inhibitory immune checkpoints including programmed death‐1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA4).315, 316